203 related articles for article (PubMed ID: 24912394)
1. Treatment persistence and switching in triptan users: a systematic literature review.
Messali AJ; Yang M; Gillard P; Tsai K; Tepper SJ; Bloudek LM; Kori SH
Headache; 2014; 54(7):1120-30. PubMed ID: 24912394
[TBL] [Abstract][Full Text] [Related]
2. Identifying the factors underlying discontinuation of triptans.
Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
[TBL] [Abstract][Full Text] [Related]
3. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
[TBL] [Abstract][Full Text] [Related]
4. The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: a systematic literature review.
Deighton AM; Harris LA; Johnston K; Hogan S; Quaranta LA; L'Italien G; Coric V
BMC Neurol; 2021 Nov; 21(1):425. PubMed ID: 34727873
[TBL] [Abstract][Full Text] [Related]
5. Effects of switching acute treatment on disability in migraine patients using triptans.
Serrano D; Buse DC; Kori SH; Papapetropoulos S; Cunanan CM; Manack AN; Reed ML; Lipton RB
Headache; 2013 Oct; 53(9):1415-29. PubMed ID: 23808937
[TBL] [Abstract][Full Text] [Related]
6. Results of a 2-year retrospective cohort study of newly prescribed triptan users in European nationwide practice databases.
Ng-Mak DS; Chen YT; Ho TW; Stanford B; Roset M
Cephalalgia; 2012 Sep; 32(12):875-87. PubMed ID: 22833612
[TBL] [Abstract][Full Text] [Related]
7. Triptan persistency among newly initiated users in a pharmacy claims database.
Katić BJ; Rajagopalan S; Ho TW; Chen YT; Hu XH
Cephalalgia; 2011 Mar; 31(4):488-500. PubMed ID: 20937605
[TBL] [Abstract][Full Text] [Related]
8. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA
Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301
[TBL] [Abstract][Full Text] [Related]
9. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
[TBL] [Abstract][Full Text] [Related]
10. Triptans for Acute Migraine Headache: Current Experience With Triptan Use and Prescription Habits in a Tertiary Care Headache Outpatient Clinic: An Observational Study.
Fischer M; Frank F; Wille G; Klien S; Lackner P; Broessner G
Headache; 2016 Jun; 56(6):952-60. PubMed ID: 27091593
[TBL] [Abstract][Full Text] [Related]
11. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
[TBL] [Abstract][Full Text] [Related]
12. Acute treatment patterns in patients with migraine newly initiating a triptan.
Lipton RB; Marcus SC; Shewale AR; Dodick DW; Viswanathan HN; Doshi JA
Cephalalgia; 2020 Apr; 40(5):437-447. PubMed ID: 32138526
[TBL] [Abstract][Full Text] [Related]
13. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Holland S; Fanning KM; Serrano D; Buse DC; Reed ML; Lipton RB
J Neurol Sci; 2013 Mar; 326(1-2):10-7. PubMed ID: 23394974
[TBL] [Abstract][Full Text] [Related]
14. Patterns of use and health expenses associated with triptans among adults with migraines.
Wu J; Noxon V; Lu ZK
Clin J Pain; 2015 Aug; 31(8):673-9. PubMed ID: 25185875
[TBL] [Abstract][Full Text] [Related]
15. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.
Cameron C; Kelly S; Hsieh SC; Murphy M; Chen L; Kotb A; Peterson J; Coyle D; Skidmore B; Gomes T; Clifford T; Wells G
Headache; 2015; 55 Suppl 4():221-35. PubMed ID: 26178694
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.
Chu MK; Buse DC; Bigal ME; Serrano D; Lipton RB
Headache; 2012 Feb; 52(2):213-23. PubMed ID: 22413150
[TBL] [Abstract][Full Text] [Related]
17. Predictors of adherence to triptans: factors of sustained vs lapsed users.
Cady RK; Maizels M; Reeves DL; Levinson DM; Evans JK
Headache; 2009 Mar; 49(3):386-94. PubMed ID: 19220501
[TBL] [Abstract][Full Text] [Related]
18. Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks.
Lee JH; Shewale AR; Barthold D; Devine B
Headache; 2021 Nov; 61(10):1499-1510. PubMed ID: 34841520
[TBL] [Abstract][Full Text] [Related]
19. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
[TBL] [Abstract][Full Text] [Related]
20. Triptan education and improving knowledge for optimal migraine treatment: an observational study.
Baron EP; Markowitz SY; Lettich A; Hastriter E; Lovell B; Kalidas K; Dodick DW; Schwedt TJ;
Headache; 2014 Apr; 54(4):686-97. PubMed ID: 24520930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
